Lilly-backed Solu stacked and ready for the clinic

10 April 2025

Solu Therapeutics, a US biotech developing therapies to eliminate disease-driving cells in cancer, immunology and other therapeutic areas, has announced the successful completion of a $41 million Series A financing.

The round included participation from five new investors - Eli Lilly (NYSE: LLY), Biovision Ventures, Pappas Capital, Hengdian Group Capital and The Leukemia & Lymphoma Society Therapy Acceleration Program - as well as continued support from existing Solu investors Longwood Fund, DCVC Bio, Santé Ventures, Astellas Venture Management and Alexandria Venture Investments.

Solu also announced the beginning of treatment of the first patient in its first-in-human Phase I trial of STX-0712 in resistant/refractory chronic myelomonocytic leukemia (CMML) and other hematologic malignancies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK